I T Rubio1, S Diaz-Botero2, A Esgueva2, R Rodriguez2, T Cortadellas2, O Cordoba2, M Espinosa-Bravo2. 1. Breast Surgical Oncology Unit, Breast Cancer Center, Hospital Universitario Vall d'Hebron, Barcelona, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain. Electronic address: irubio@vhio.net. 2. Breast Surgical Oncology Unit, Breast Cancer Center, Hospital Universitario Vall d'Hebron, Barcelona, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain.
Abstract
BACKGROUND: Preoperative injection of Tc99 is standardly performed before sentinel lymph node biopsy (SLN) for breast cancer. Multiple questions have arisen concerning appropriate technique for SLNBs including site of injection, timing and injection material. The aim of this study was to assess the concordance between a new method, superparamagnetic iron oxide (SPIO) and the Tc99 radiotracer to identify the SLN in early breast cancer. MATERIAL AND METHODS: Between July 2013 and March 2014, 120 patients with clinically node negative early breast cancer were included in the study. Patients were injected the day before the radiotracer for lymphoscintigraphy and injected the SPIO subareolar intraoperatively. SLN was excised if it was radioactive, magnetic or palpable. Patients signed an inform consent. RESULTS: There was no drainage by either technique in 2 patients, so this leaves 118 patients for further analysis. Detection rate by Tc 99 was successful in 113 (95.7%%) patients and by SPIO in 116 (98.3%). Concordance rates per patient between techniques was 98.2%. The SLN was positive in 36 (30%) patients. Of this, SLN positivity was detected by both techniques in 32 patients. Mean number of SLNs by 99Tc and SPIO were 1.9 and 2.21 respectively (p = 0.001). DISCUSSION: Detection of SLNs with SPIO allows for easy identification of axillary nodes, at a frequency not inferior to the radiotracer. It is an oncologically safe procedure, facilitates patients and operative room management and can be used to reliably identify SLNs in breast cancer.
BACKGROUND: Preoperative injection of Tc99 is standardly performed before sentinel lymph node biopsy (SLN) for breast cancer. Multiple questions have arisen concerning appropriate technique for SLNBs including site of injection, timing and injection material. The aim of this study was to assess the concordance between a new method, superparamagnetic iron oxide (SPIO) and the Tc99 radiotracer to identify the SLN in early breast cancer. MATERIAL AND METHODS: Between July 2013 and March 2014, 120 patients with clinically node negative early breast cancer were included in the study. Patients were injected the day before the radiotracer for lymphoscintigraphy and injected the SPIO subareolar intraoperatively. SLN was excised if it was radioactive, magnetic or palpable. Patients signed an inform consent. RESULTS: There was no drainage by either technique in 2 patients, so this leaves 118 patients for further analysis. Detection rate by Tc 99 was successful in 113 (95.7%%) patients and by SPIO in 116 (98.3%). Concordance rates per patient between techniques was 98.2%. The SLN was positive in 36 (30%) patients. Of this, SLN positivity was detected by both techniques in 32 patients. Mean number of SLNs by 99Tc and SPIO were 1.9 and 2.21 respectively (p = 0.001). DISCUSSION: Detection of SLNs with SPIO allows for easy identification of axillary nodes, at a frequency not inferior to the radiotracer. It is an oncologically safe procedure, facilitates patients and operative room management and can be used to reliably identify SLNs in breast cancer.
Authors: Christina Bluemel; Domenico Rubello; Patrick M Colletti; Remco de Bree; Ken Herrmann Journal: Eur J Nucl Med Mol Imaging Date: 2015-04-28 Impact factor: 9.236
Authors: Joost J Pouw; Maarten R Grootendorst; Roland Bezooijen; Caroline A H Klazen; Wieger I De Bruin; Joost M Klaase; Margaret A Hall-Craggs; Michael Douek; Bennie Ten Haken Journal: Br J Radiol Date: 2015-10-22 Impact factor: 3.039
Authors: Andreas Karakatsanis; Peer Michael Christiansen; Lone Fischer; Christina Hedin; Lida Pistioli; Malin Sund; Nils Ryegaard Rasmussen; Hjørdis Jørnsgård; Daniel Tegnelius; Staffan Eriksson; Kosmas Daskalakis; Fredrik Wärnberg; Christos J Markopoulos; Leif Bergkvist Journal: Breast Cancer Res Treat Date: 2016-04-27 Impact factor: 4.872